ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score

Thursday, August 7, 2014

Submitted by

Mark Ferguson

Source

Source Name: Thorax

Source URL: http://thorax.bmj.com/content/early/2014/08/06/thoraxjnl-2014-205285?papetoc

Author(s)

Amelia O Clive, Brennan C Kahan, Clare E Hooper, Rahul Bhatnagar, Anna J Morley, Natalie Zahan-Evans, Oliver J Bintcliffe, Rogier C Boshuizen, Edward T H Fysh, Claire L Tobin, Andrew R L Medford, John E Harvey, Michel M van den Heuvel, Y C Gary Lee, Nick A Maskell

The authors developed and validated a survival predictive score for patients with malignant pleural effusion using 3 large international cohorts of patients. The LENT score is based on LDH level, ECOG performance status, neutrophil to lymphocyte ratio, and tumor type. Low risk patients had a median survival of 319 days, moderate risk group survival was 130 days, and median survival in the high risk group was 44 days. Among the high risk patients, mortality at 1 month was 35% and at 6 months was 97%. Use of this score may help in selecting appropriate interventions for this patient population.